Designated model MOR-2AM4FB-PG, the product 2-Aminomethyl-4-(4-fluorobenzyl)-morpholine biocatalysts Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is supplied as a white to off-white crystalline powder with molecular formula C12H17FN2O and molecular weight 224.28 g/mol. The term “biocatalysts” in the product designation refers to the enzyme-mediated stereoselective step used to establish the C2 aminomethyl stereocentre; the final API is not an immobilised enzyme preparation. The material is released under ICH Q7 quality systems, with residual solvent testing aligned to USP <467> and elemental impurity control aligned to ICH Q3D. Oral and injectable supply points are separated by particle engineering, bioburden, endotoxin, and packaging rather than by molecular structure.

Because the C2 position bears an aminomethyl substituent, the molecule is chiral at the morpholine ring carbon; the biocatalytic route is therefore designed to deliver a defined enantiomer rather than a racemic mixture. The primary amine provides a site for acid addition salt formation, but it also creates incompatibility with aldehyde-based excipients and reducing sugars. Salt selection must be fixed before tablet, capsule, or injectable formulation because the hydrochloride and mesylate salts differ in hygroscopicity, aqueous solubility, and compactability. Published data for this exact compound are limited, so enantiomeric excess, specific rotation, and salt-release limits should be fixed against the supplier certificate of analysis and qualification batches under ICH Q6A.

What changes when a 4-fluorobenzyl substituent replaces a simple benzyl or methyl group on the morpholine nitrogen?

The para-fluoro substituent withdraws electron density from the morpholine nitrogen, reducing proton affinity relative to a nonfluorinated benzyl analogue. This changes salt-selection behaviour: the free base is less readily protonated at formulation pH, and dissolution in unbuffered tablet media may be slower unless a preformed salt is used. The fluorinated ring also increases the molecule’s lipophilicity and alters its reversed-phase retention, which simplifies HPLC-UV detection at 210–230 nm compared with nonaromatic morpholine. Unlike simple morpholine, the 2-aminomethyl side chain is a primary amine that can form amides, imines, or Maillard products; therefore lactose and crospovidone-based formulations should be screened for stability under ICH Q1A(R2). The compound also has a higher molecular weight and lower vapour pressure than unsubstituted morpholine, reducing open-transfer losses on production-scale dispensing.

No single pharmacopoeial monograph exists for 2-aminomethyl-4-(4-fluorobenzyl)-morpholine biocatalysts Pharma Grade API; therefore the release specification is assembled from ICH Q7 and dosage-form-specific pharmacopoeial chapters. The table below summarises the model grades and the primary controls applied at release.

Residual solvents are controlled under USP <467>; methanol, ethanol, isopropanol, and ethyl acetate are typically limited as Class 3 solvents, while dichloromethane, if used in purification, is limited as a Class 2 solvent. Elemental impurities are assessed according to ICH Q3D, with particular attention to palladium, nickel, and chromium if the biocatalytic process uses metal-complex cofactors. For injectable grade, bacterial endotoxins must be set from the maximum adult dose and are commonly below 0.25 EU/mg for high-dose parenterals, but the registered limit must be formulation-specific.

When the API is processed by wet granulation rather than direct compression

Wet granulation of the free base is generally avoided because aqueous solubility at neutral pH is limited; a preformed acid addition salt, typically the hydrochloride, is dispersed in the binder solution. In a production-scale high-shear granulator with a 65 L bowl, impeller tip speed of 4.0 m/s, and side-chopper speed of 1500 min⁻¹, primary amine APIs of similar molecular weight can reach granule D50 between 100 µm and 250 µm; however, published data for this specific compound are limited. End-point should be determined by torque or power consumption, not fixed time, because batch-to-batch variation in residual water or solvent can alter liquid demand. Drying should maintain product temperature below 40 °C unless forced-degradation data support a higher range. If the processing room exceeds 60% RH, pre-drying of the API and excipients is required to prevent caking and weight variation.

On a rotary tablet press operating above 60,000 tablets/h, direct-compression blends containing a micronised free base can exhibit die-fill weight variation outside USP <905> if the D90 is too large or too small. As a general geometric rule, the API D90 should be no greater than one-third of the smallest die diameter; for a 6 mm die, this corresponds to a D90 below 180 µm. The free base is cohesive after jet milling, so flow function coefficient and wall friction angle should be measured with a Schulze ring shear tester before compression. If the flow function coefficient is below 4, dry granulation or roller compaction is required.

Capsule filling on dosator or tamping-pin machines requires a blend flow function coefficient above 4 to avoid ratholing and to keep fill-weight relative standard deviation within ±3% at speeds exceeding 50,000 capsules/h. The capsule grade is therefore not simply a jet-milled powder; it is a controlled-particle-size material, optionally co-processed with colloidal silicon dioxide at 0.5–1.0% w/w. The primary chemical difference from tablet grade is absent; the distinction lies in particle-size distribution, bulk density, and residual water.

For granule-based sachets or dispersible tablets, drug-layering on microcrystalline cellulose spheres in a fluid-bed coater with Wurster insert is preferred when a ready-to-use granule is required. The aminomethyl side chain can interact with anionic polymers such as carbomer or sodium alginate; this can delay release if the formulation contains these matrix polymers. The effect is not observed with unsubstituted morpholine because the primary amine is absent, which is a key differentiating factor in controlled-release granule design. Coating efficiency and dissolution after curing should be monitored under USP <711> because slow ionization of the primary amine in acidic coating solutions can alter release.

The main operational difference from unsubstituted morpholine is the combination of a chiral C2 centre and a primary amine side chain. Unsubstituted morpholine is typically released as a technical-grade liquid with gas-chromatographic controls; it is not ordinarily supplied with a sterility, endotoxin, or enantiomeric excess certificate. The 4-fluorobenzyl group further distinguishes this product from nonfluorinated 4-benzylmorpholine: the para-fluoro substituent changes basicity, lipophilicity, and ultraviolet detection but does not, by itself, create a new chromophore. The table below summarises the comparison.

Because the product is produced through a biocatalytic step, trace enzyme, host-cell proteins, and carbohydrate residues may be present unless the API is ultrafiltered through a 10 kDa nominal molecular weight cut-off. In injectable applications, an ELISA or Bradford assay may be included as a release panel to demonstrate that proteinaceous impurities are below the level that could aggregate during storage. Simple morpholine derivatives do not require protein-specific testing, so this is an additional regulatory interface for the biocatalysts Pharma Grade API.

Reversed-phase HPLC with a C18 column and a mobile phase containing phosphate buffer at pH 3.0 and acetonitrile resolves the API from process impurities; the fluorinated benzyl ring provides absorbance at 210–230 nm. Chiral purity is measured with a polysaccharide-based chiral stationary phase, such as amylose tris(3,5-dimethylphenylcarbamate), because the C2 aminomethyl substituent creates enantiomers that may differ in pharmacological activity. Unless the product is a single enantiomer, the opposite enantiomer is treated as a specified impurity with a limit derived from batch data and ICH Q3A. Simple morpholine derivatives do not require this chiral assay because they lack the C2 stereocentre.

Binary compatibility studies with mannitol, dicalcium phosphate dihydrate, microcrystalline cellulose, and crospovidone should be performed under ICH Q1A(R2) accelerated conditions. The primary amine can interact with lactose to form Maillard products; therefore lactose-containing tablet and capsule formulations should be avoided unless the product is a stable acid addition salt and storage moisture is maintained below 60% RH. If lactose is unavoidable, a limit on the Amadori rearrangement product should be included in the degradation specification. These interactions are not observed with simple morpholine derivatives lacking the primary amine.

Process validation for oral solid dosage forms should include compaction profile, ejection force, and content uniformity. When the API is roller-compacted, roll pressure and gap should be monitored because the primary amine salt may soften under pressure and generate granules with high fines. If the granule D50 shifts below 100 µm, tablet weight variation can exceed ±2% relative standard deviation. The product’s difference from non-aminated morpholine intermediates is that the salt form has a measurable compactability threshold; no published data for this exact compound are available to replace development-scale studies.

Store in tight, moisture-proof containers at 2–8 °C or 25 °C/60% RH as specified by the certificate of analysis. The free base should be protected from carbon dioxide because the primary amine can form carbamate salts on long-term storage. Photostability testing under ICH Q1B should be performed if the product is exposed to light during granule or solution manufacturing. The fluorinated benzyl group may shift UV absorption but does not eliminate the need for light protection.

Injectable-grade constraints under terminal sterilisation and aseptic crystallisation

The injectable grade is controlled for particulate matter under USP <788> and USP <790>; visible particulates are especially relevant when the API is lyophilised for reconstitution. If terminal sterilisation by autoclaving at 121 °C for 15 min is required, the hydrochloride salt must be evaluated for hydrolytic degradation of the aminomethyl side chain and for fluorobenzyl C–N cleavage under forced-degradation conditions. If terminal sterilisation is not feasible, sterile filtration and aseptic crystallisation are used. The 4-fluorobenzyl group is expected to reduce aqueous solubility of the free base relative to the nonfluorinated benzyl analogue; because published solubility data for this exact compound are limited, formulation pH and salt concentration must be established by shake-flask method according to OECD 105 or equivalent. Injectable formulations usually use a pH-adjusted salt solution below pH 4.0 to maintain dissolution, but the registered pH boundary must be supported by stability data under ICH Q1A(R2).

The chemical identity of oral and injectable grades is identical; the difference lies in microbial quality, particulate matter, residual protein, and packaging. Injectable grade is supplied in amber Type I glass vials sealed under nitrogen, while oral grades may be supplied in double polyethylene bags inside fibre drums. This segregation follows material-handling expectations in FDA 21 CFR Part 211 and ICH Q7. For tablet and capsule manufacture, the product should be handled in a containment system if the D50 is below 5 µm because dusting losses during bin charging may affect batch mass and operator exposure. For injectable compounding, the API should be dissolved in water for injection under aseptic conditions and filtered through a 0.22 µm sterilising-grade membrane before lyophilisation or final sterile fill.